Carotid Artery Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major carotid artery disease markets are expected to exhibit a CAGR of 3.03% during 2024-2034.
The carotid artery disease market has been comprehensively analyzed in IMARC's new report titled "Carotid Artery Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Carotid artery disease, also known as carotid artery stenosis, occurs when the carotid arteries, which supply oxygenated blood to the brain, become narrowed or get blocked. The most common symptom is transient ischemic attacks, characterized by temporary episodes of neurological dysfunction, such as numbness, slurred speech, vision changes, etc. Various other indications include sudden and severe headaches, dizziness, difficulty with coordination, confusion, facial drooping, etc. In advanced stages, carotid artery disease can lead to a complete blockage of blood flow, resulting in a stroke. Diagnosing the ailment typically involves a combination of medical history assessment, physical examination, and diagnostic tests. The healthcare provider will inquire about risk factors, symptoms, and previous medical conditions during the evaluation. A physical exam may include assessing blood pressure, listening for abnormal sounds in the carotid arteries, and evaluating neurological function. Numerous diagnostic tests, such as carotid ultrasound, magnetic resonance angiography, computed tomography angiography, etc., are commonly used to visualize the carotid arteries and assess the degree of stenosis. Additionally, an electrocardiogram may be performed to determine overall cardiovascular health and identify any associated conditions.
The increasing prevalence of atherosclerosis, which is characterized by the accumulation of plaque in the artery walls, thereby resulting in the narrowing of the carotid arteries, is primarily driving the carotid artery disease market. In addition to this, the rising incidence of numerous risk factors, including hypertension, diabetes, obesity, elevated levels of low-density lipoprotein cholesterol, certain inflammatory conditions like rheumatoid arthritis, etc., is also bolstering the market growth. Moreover, the escalating usage of antiplatelet drugs, such as clopidogrel and ticagrelor, for reducing the likelihood of blood clot formation in the carotid arteries is creating a positive outlook for the market. Besides this, the inflating utilization of carotid endarterectomy, which involves making an incision in the neck, accessing the affected artery, and removing the plaque to restore blood flow, in patients at high risk for stroke, is also augmenting the market growth. Furthermore, the ongoing advancements in endovascular techniques, including the introduction of transcarotid artery revascularization and transradial carotid artery stenting, which are less invasive with reduced likelihood of complications, are expected to drive the carotid artery disease market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the carotid artery disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for carotid artery disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the carotid artery disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the carotid artery disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the carotid artery disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current carotid artery disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the carotid artery disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the carotid artery disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the carotid artery disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of carotid artery disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of carotid artery disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of carotid artery disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with carotid artery disease across the seven major markets?
What is the size of the carotid artery disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of carotid artery disease?
What will be the growth rate of patients across the seven major markets?
Carotid Artery Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for carotid artery disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the carotid artery disease market?
What are the key regulatory events related to the carotid artery disease market?
What is the structure of clinical trial landscape by status related to the carotid artery disease market?
What is the structure of clinical trial landscape by phase related to the carotid artery disease market?
What is the structure of clinical trial landscape by route of administration related to the carotid artery disease market?
The carotid artery disease market has been comprehensively analyzed in IMARC's new report titled "Carotid Artery Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Carotid artery disease, also known as carotid artery stenosis, occurs when the carotid arteries, which supply oxygenated blood to the brain, become narrowed or get blocked. The most common symptom is transient ischemic attacks, characterized by temporary episodes of neurological dysfunction, such as numbness, slurred speech, vision changes, etc. Various other indications include sudden and severe headaches, dizziness, difficulty with coordination, confusion, facial drooping, etc. In advanced stages, carotid artery disease can lead to a complete blockage of blood flow, resulting in a stroke. Diagnosing the ailment typically involves a combination of medical history assessment, physical examination, and diagnostic tests. The healthcare provider will inquire about risk factors, symptoms, and previous medical conditions during the evaluation. A physical exam may include assessing blood pressure, listening for abnormal sounds in the carotid arteries, and evaluating neurological function. Numerous diagnostic tests, such as carotid ultrasound, magnetic resonance angiography, computed tomography angiography, etc., are commonly used to visualize the carotid arteries and assess the degree of stenosis. Additionally, an electrocardiogram may be performed to determine overall cardiovascular health and identify any associated conditions.
The increasing prevalence of atherosclerosis, which is characterized by the accumulation of plaque in the artery walls, thereby resulting in the narrowing of the carotid arteries, is primarily driving the carotid artery disease market. In addition to this, the rising incidence of numerous risk factors, including hypertension, diabetes, obesity, elevated levels of low-density lipoprotein cholesterol, certain inflammatory conditions like rheumatoid arthritis, etc., is also bolstering the market growth. Moreover, the escalating usage of antiplatelet drugs, such as clopidogrel and ticagrelor, for reducing the likelihood of blood clot formation in the carotid arteries is creating a positive outlook for the market. Besides this, the inflating utilization of carotid endarterectomy, which involves making an incision in the neck, accessing the affected artery, and removing the plaque to restore blood flow, in patients at high risk for stroke, is also augmenting the market growth. Furthermore, the ongoing advancements in endovascular techniques, including the introduction of transcarotid artery revascularization and transradial carotid artery stenting, which are less invasive with reduced likelihood of complications, are expected to drive the carotid artery disease market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the carotid artery disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for carotid artery disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the carotid artery disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the carotid artery disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the carotid artery disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current carotid artery disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the carotid artery disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the carotid artery disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the carotid artery disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of carotid artery disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of carotid artery disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of carotid artery disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with carotid artery disease across the seven major markets?
What is the size of the carotid artery disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of carotid artery disease?
What will be the growth rate of patients across the seven major markets?
Carotid Artery Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for carotid artery disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the carotid artery disease market?
What are the key regulatory events related to the carotid artery disease market?
What is the structure of clinical trial landscape by status related to the carotid artery disease market?
What is the structure of clinical trial landscape by phase related to the carotid artery disease market?
What is the structure of clinical trial landscape by route of administration related to the carotid artery disease market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CAROTID ARTERY DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CAROTID ARTERY DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CAROTID ARTERY DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CAROTID ARTERY DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CAROTID ARTERY DISEASE - UNMET NEEDS
10 CAROTID ARTERY DISEASE - KEY ENDPOINTS OF TREATMENT
11 CAROTID ARTERY DISEASE - MARKETED PRODUCTS
11.1 List of Carotid Artery Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CAROTID ARTERY DISEASE - PIPELINE DRUGS
12.1 List of Carotid Artery Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. CAROTID ARTERY DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CAROTID ARTERY DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CAROTID ARTERY DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Carotid Artery Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Carotid Artery Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Carotid Artery Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Carotid Artery Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Carotid Artery Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Carotid Artery Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Carotid Artery Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Carotid Artery Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Carotid Artery Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Carotid Artery Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Carotid Artery Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Carotid Artery Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Carotid Artery Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Carotid Artery Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Carotid Artery Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Carotid Artery Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Carotid Artery Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Carotid Artery Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Carotid Artery Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Carotid Artery Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Carotid Artery Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Carotid Artery Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Carotid Artery Disease - Access and Reimbursement Overview
16 CAROTID ARTERY DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CAROTID ARTERY DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CAROTID ARTERY DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CAROTID ARTERY DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CAROTID ARTERY DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CAROTID ARTERY DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CAROTID ARTERY DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CAROTID ARTERY DISEASE - UNMET NEEDS
10 CAROTID ARTERY DISEASE - KEY ENDPOINTS OF TREATMENT
11 CAROTID ARTERY DISEASE - MARKETED PRODUCTS
11.1 List of Carotid Artery Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CAROTID ARTERY DISEASE - PIPELINE DRUGS
12.1 List of Carotid Artery Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. CAROTID ARTERY DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CAROTID ARTERY DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CAROTID ARTERY DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Carotid Artery Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Carotid Artery Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Carotid Artery Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Carotid Artery Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Carotid Artery Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Carotid Artery Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Carotid Artery Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Carotid Artery Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Carotid Artery Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Carotid Artery Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Carotid Artery Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Carotid Artery Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Carotid Artery Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Carotid Artery Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Carotid Artery Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Carotid Artery Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Carotid Artery Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Carotid Artery Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Carotid Artery Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Carotid Artery Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Carotid Artery Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Carotid Artery Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Carotid Artery Disease - Access and Reimbursement Overview
16 CAROTID ARTERY DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CAROTID ARTERY DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CAROTID ARTERY DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
